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background: Coronary artery disease (CAD) is frequently present in patients with aortic stenosis (AS). Simultaneous coronary 
revascularization at the time of surgical valve replacement is associated with increased morbidity and mortality. Patients with AS and 
significant CAD may require percutaneous coronary intervention (PCI) to avoid hemodynamic compromise during transcatheter aortic valve 
replacement (TAVR). However, the impact of simultaneous PCI on the outcomes of TAVR is not well established.
methods: We performed a retrospective single center analysis of 45 consecutive patients that underwent concomitant TAVR and PCI. The 
decision to perform PCI in addition to TAVR was made by the heart team and primarily performed in patients with severe proximal disease 
and large ischemic territories.
results: Mean age was 84 years, with 47% males. Patients had symptomatic AS with an average aortic valve area of 0.72 cm2 and a 
mean gradient of 43 mmHg. The patients were high risk for surgical AVR with coronary revascularization (mean STS score 8.7%). The 
comorbidity profile was extensive, including hypertension (91%), diabetes (22%), peripheral vascular disease (20%), cerebrovascular 
disease (16%), atrial fibrillation (29%), and lung disease (22%). All patients had CAD with 27% prior MIs, 24% prior PCIs, and 13% prior 
CABG. All TAVR and PCI procedures were successful. Most PCIs involved single vessels (96%), with 7% Left Main Trunk and 60% LAD 
interventions. The 30-day mortality was 2.2% and the 1-year mortality was 11.1%. We observed no procedure related MIs or strokes. The 
rates of major and minor vascular complications were 4% each. Serious bleeding occurred in 7% and minor bleeds in 13% of patients. Of 
note, no patients developed acute renal failure.
Conclusion:  Simultaneous TAVR and PCI is a feasible treatment strategy for patients that are high risk for surgery. The procedural 
outcomes of this retrospective single center study compare favorably to previously reported outcomes with TAVR alone. However, 
randomized controlled trials are needed to guide patient selection and further investigate the optimal percutaneous treatment strategies for 
patients with severe AS and CAD.
